Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.03.31.535103

Xylazine effects on opioid-induced brain hypoxia

Abstract

Xylazine has emerged in recent years as an adulterant in an increasing number of opioid-positive overdose deaths in the United States. Although its exact role in opioid-induced overdose deaths is largely unknown, xylazine is known to depress vital functions and cause hypotension, bradycardia, hypothermia, and respiratory depression. In this study, we examined the brain-specific hypothermic and hypoxic effects of xylazine and its mixtures with fentanyl and heroin in freely moving rats. In the temperature experiment, we found that intravenous xylazine at low, human-relevant doses (0.33, 1.0, 3.0 mg/kg) dose-dependently decreases locomotor activity and induces modest but prolonged brain and body hypothermia. In the electrochemical experiment, we found that xylazine at the same doses dose-dependently decreases nucleus accumbens oxygenation. In contrast to relatively weak and prolonged decreases induced by xylazine, intravenous fentanyl (20 g/kg) and heroin (600 g/kg) induce stronger biphasic brain oxygen responses, with the initial rapid and strong decrease, resulting from respiratory depression, followed by a slower, more prolonged increase reflecting a post-hypoxic compensatory phase, with fentanyl acting much quicker than heroin. The xylazine-fentanyl mixture eliminated the hyperoxic phase of oxygen response and prolonged brain hypoxia, suggesting xylazine-induced attenuation of the brains compensatory mechanisms to counteract brain hypoxia. The xylazine-heroin mixture strongly potentiated the initial oxygen decrease, and the pattern lacked the hyperoxic portion of the biphasic oxygen response, suggesting more robust and prolonged brain hypoxia. These findings suggest that xylazine exacerbates the life-threatening effects of opioids, proposing worsened brain hypoxia as the mechanism contributing to xylazine-positive opioid-overdose deaths.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Choi, S., Irwin, M. R., Kiyatkin, E.. 2023-04-03. Xylazine effects on opioid-induced brain hypoxia. https://doi.org/10.1101/2023.03.31.535103

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Distinct changes in brain and peripheral oxygen levels induced by synthetic opioids of the nitazene family

Nitazenes are a category of synthetic opioids, some of which have high analgesic potential but also high toxicity, which has historically prevented their development as therapeutic drugs. Like fentanyl, nitazenes induce respiratory depression, a primary factor in their toxicity. Recently, a nitazene derivative called N-desethyl-fluornitrazene (DFNZ) was shown to have high analgesic properties with weak hypoxic effects. To better characterize the hypoxic effects of DFNZ relative to its parent, fluornitrazene (FNZ) and the prototypical nitazene etonitazene, we used amperometric oxygen sensors in freely moving rats to examine oxygen dynamics in the nucleus accumbens (NAc) and the subcutaneous space, using fentanyl as a comparison. All drugs induced similar patterns of subcutaneous hypoxia, with rapid dose-dependent oxygen decreases. In the NAc, all opioids, except DFNZ, at low iv doses (1-5 g/kg) induced moderate but significant brain oxygen increases. At higher doses (>10 g/kg), oxygen levels for all opioids, except DFNZ, showed a biphasic response; robust hypoxia followed by a weaker rebound-like hyperoxia. Etonitazene at 30 g/kg had the largest and most prolonged brain hypoxia compared to the other drugs, without the rebound-like hyperoxia. These findings indicate that etonitazene and FNZ mimic the effects of fentanyl, inducing dose-dependent brain and peripheral hypoxia. In contrast, DFNZ induces very weak hypoxia seen minimally at very high iv doses (300-1000 g/kg). Our findings substantiate the low hypoxic potency of DFNZ and indicate that not all nitazenes are characterized by high potential for toxicity. As such, the development of nitazenes as analgesics should not be categorically dismissed.

pharmacology and toxicology↗

The key role of oxidation state and flake size in the ecotoxicological impact of industrial graphene oxide nanoflakes

Graphene oxide (GO) is a widely used nanomaterial across various scientific and technological fields. Environmental exposure to GO and consequent ecotoxicological effects have been largely reported. Despite the significant efforts and illuminating conclusions, establishing fair pairwise correlations between material and toxicity descriptors remains challenging and controversial. Key drawbacks in GO ecotoxicological studies to date include a lack of standardized materials, poorly defined descriptors, and insufficient material variants. Here, we establish the first comprehensive framework to tackle the multidimensional ecotoxicology of GO. We perform thorough material characterization to derive descriptors that precisely define four key GO variants used in industrial scale-up, with differing flake granularity and oxidation extent. These GO variants are evaluated against toxicological endpoint descriptors across two animal models (Daphnia magna and Caenorhabditis elegans) and two plant models (rice and pepper). Our findings underscore the inherently multidimensional nature of GO toxicity by identifying key physicochemical properties associated with it. This study provides an unprecedented platform for parametrizing GO materials using material and toxicity descriptors to contribute to nanomaterial safety.

pharmacology and toxicology↗

The activation-deactivation cycle of human PIEZO1

PIEZO1 is a cation channel that is primarily activated through mechanical force, and activation has been shown to be influenced by membrane curvature. PIEZO1 is ubiquitously expressed and plays critical roles in various patho-/physiological processes such as inflammatory diseases or red blood cell volume regulation. Here we combine coarse-grained and atomistic simulations in which human PIEZO1 is embedded in a curved membrane and subjected to simulations under controlled membrane tension and a physiological transmembrane potential, allowing the gating cycle to be reconstructed at atomic resolution. Systematic pressure adaptation identifies an activation regime in which the channel flattens progressively, and ion permeation quantitatively reproduces the experimental conductance of 36 pS. Furthermore, the R2456-E2117 salt bridge couples pore lipid retention to the anchor domain and disrupting it reproduces the phenotypes of the disease-associated R2456H and R2456C variants. PIEZO activation is transmitted through an interconnected network of contact rearrangements that ultimately reshapes the yoda1 binding pocket at the THU8/THU9 interface. This state-dependent remodelling rationalises the pharmacology of yoda1 and offers a framework for the structure-based design of PIEZO1 modulators.

pharmacology and toxicology↗